Planned
LondonUnited Kingdom
Our planned European base, centred on clinical partnerships, regulatory engagement with the MHRA, and translational research.
Concept phaseLondon · San Francisco
Extending healthy human life, by design.
Circularity Health is building the research and technology platform for longevity, resilience and life expansion.
51.5072° N
London, United Kingdom
37.7749° N
San Francisco, USA
Concept imagery
Circularity LabsLife-expansion R&D, from measurement to intervention
Measure
Establish what ageing actually looks like in a body: biomarkers, biological age and longitudinal baselines.
Intervene
Research cellular clean-up, partial reprogramming and precision editing, with safety limits built into every design.
Extend
Aim to extend healthy, resilient years rather than lifespan alone — function first, duration second.
Research areas
Six lines of enquiry, one platform.
Each area is at a different stage of maturity. All of them are researched openly, with an emphasis on what can be validated rather than what can be promised.
All programmes are at research or concept stage. No product, therapy or clinical service is offered.
Concept phase
Start a conversationNow forming founding partnerships.
Circularity Health is assembling its first research collaborations ahead of pilot work. We are speaking with academic groups, clinicians, biotech teams and long-horizon investors.
Planned hubs
Two cities, one research programme.
We are planning a two-hub model: European clinical and regulatory depth in London, paired with computational and engineering capability in San Francisco.
Planned
San FranciscoUnited States
Our planned technology and data base, focused on AI-driven discovery, engineering and work toward FDA-facing programmes.
Why now
Three shifts make this moment different.
01
AI is accelerating biological discovery
Predictive models now explore protein and cellular design spaces at a pace laboratory work alone cannot match — compressing years of candidate search into weeks of validation.
02
Cellular rejuvenation is entering clinical research
Senolytic and partial-reprogramming approaches are moving from cell culture into early-stage human studies, with safety questions still very much open.
03
Access and safety must be designed in from day one
If these technologies work, the terms on which they reach people will matter as much as the science. We are building those constraints into the research plan, not adding them later.
These are research directions, not clinical claims. Any future therapy would require regulatory approval, and none is offered today.
Research notes
Occasional letters on longevity science — written carefully.
Programme updates, reading from the field, and notes on the ethics of life extension. No hype, no promises, roughly once a month.